- Pin
- ⏰ Just a Few Days Left!
🔥 The 12th Anniversary Celebration is Ending Soon — Don’t Miss Your Chance to Claim Rewards
🚀 Limited-Time Revelry #5 is Live
👉 Log in & play to win iPhone 16 Pro, MacBook Air and more: https://www.gate.com/activities/12th-anniversary
🏆 Draw for merch & send greetings on the Greeting Wall to win exclusive merch prizes
More Details: https://www.gate.com/announcements/article/44624
#Gate12Years#
- 🔥 Gate Post Ambassador Exclusive Posting Reward Task Round 2 Is On! 🏆 Round 1 winners will be announced on May 26!
Sign up now 👉 https://www.gate.com/questionnaire/6722
Registration Period 🕙 May 23, 03:00 AM – May 26, 04:00 PM UTC
✍️ Post daily from May 26 to June 1 and share a $300 prize pool based on your post quality!
🎁 Reward Details:
S-Level Weekly Ranking Reward
Post every day for 7 days with an overall quality score above 90 to qualify for S-Level.
2 outstanding ambassadors will each receive a $50 trading fee rebate voucher.
A/B-Level Tiered Rewards
Based on the number of posts and
- 🎉 #Gate Post# Hits 50,000 Followers!
✨ To celebrate this amazing milestone, we're giving back to our incredible community!
🎁 4 Lucky Winners Will Each Receive $10 Points!
Join:
1️⃣ Follow Gate_Post
2️⃣ Like this post
3️⃣ Drop your congratulations in the comments!
End at 18:00, May 25 (UTC)
- 🔥 Gate Post Ambassador Exclusive Posting Reward Task Is On!
👉 Post daily from May 19 to May 25 and share a $300 prize pool based on your post quality!
Join now: https://www.gate.io/questionnaire/6679
Registration deadline: May 20 10:00 UTC
🎁 Reward Details:
S-Level Weekly Ranking Reward
Post every day for 7 days with an overall quality score above 90 to qualify for S-Level.
2 outstanding ambassadors will each receive a $50 trading fee rebate voucher.
A/B-Level Tiered Rewards
Based on the number of posts and their quality, ambassadors will be ranked and rewarded accordingly:
A-Level:
Post on
Novo Nordisk: 7.2mg semaglutide phase 3 clinical trial met the primary endpoint with a weight loss of 20.7% at 72 weeks.
On January 18, Jins data reported that on January 17 local time, Novo Nordisk announced the main results of the 3b phase clinical trial STEP UP. In the STEP UP obesity trial, subcutaneous injection of 7.2mg semaglutide once a week resulted in a weight loss of 20.7% at 72 weeks, and a weight loss of 18.7% regardless of treatment compliance. The trial met its primary endpoint, with 7.2mg semaglutide showing statistically significant and superior weight loss compared to placebo at 72 weeks.